
AIM ImmunoTech completes last dose in Phase 2 pancreatic cancer trial ahead of schedule, with results expected in 2027.
AIM ImmunoTech announced that the final patient has received their last dose in the Phase 2 DURIPANC trial testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer, ahead of schedule. The primary endpoint analysis will st...

